Pharmacology of aconitine-induced automaticity on in vitro cat myocardial preparations. II. Effects of refractory period prolongation, reduced sodium and tetrodotoxin.
D031841:Aconitum / Q000494:pharmacology*; D000818:Animals; D001949:Bretylium Compounds / Q000494:pharmacology; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004983:Ethanolamines / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008012:Lidocaine / Q000494:pharmacology; D009431:Neural Conduction / Q000187:drug effects*; D010210:Papillary Muscles / Q000187:drug effects; D010477:Perfusion; D010539:Permeability; D010672:Phenytoin / Q000494:pharmacology; D011217:Practolol / Q000494:pharmacology; D011342:Procainamide / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011802:Quinidine / Q000494:pharmacology; D012032:Refractory Period, Electrophysiological / Q000187:drug effects*; D012964:Sodium / Q000494:pharmacology*; D013779:Tetrodotoxin / Q000494:pharmacology*; D013997:Time Factors
D001949:Bretylium Compounds; D004983:Ethanolamines; D013779:Tetrodotoxin; D010672:Phenytoin; D008012:Lidocaine; D012964:Sodium; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide; D011217:Practolol